
Biotechnology · Nasdaq: ALNY
Alnylam earnings: results, call transcripts & KPI history
2 quarters · fiscal year ends December · next results expected around 11 Feb 2027
Latest: Q3 2026
Alnylam enlarged its TRITON-CM nucresiran trial to about 2,250 patients, keeping a 2030 ATTR-CM launch, while AMVUTTRA's cardiomyopathy launch kept driving TTR growth.
AMVUTTRA's ATTR-CM launch remained the main driver of demand. U.S. prescriptions grew about 70% year over year, and more than 2,000 new prescribers have been added since March 2025. Abroad, ATTR-CM launches in Japan, Germany and Italy added to growth. New HELIOS-B analyses showed consistent benefit with or without baseline tafamidis. Brezosiran, for Huntington's disease, showed a 60-64% mean reduction of mutant huntingtin in spinal fluid.
Quarters
KPI history
Fourth quarter worked out from the annual figure.
Data
| Q4 2024 | $593.2M * |
| Q1 2025 | $594.2M |
| Q2 2025 | $773.7M |
| Q3 2025 | $1.2B |
| Q4 2025 | $1.1B * |
| Q2 2026 | $1.3B |
| Q3 2026 | $1.5B |
Data
| Q1 2025 | -$0.14 |
| Q2 2025 | -$0.55 |
| Q3 2025 | $2.14 |
| Q2 2026 | $1.21 |
| Q3 2026 | $15.72 |
Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.
Data
| Q4 2024 | -17.7% |
| Q1 2025 | 3.0% |
| Q2 2025 | -2.1% |
| Q3 2025 | 29.5% |
| Q4 2025 | 12.0% |
| Q2 2026 | 17.9% |
| Q3 2026 | 23.7% |
Data
| Q4 2024 | -$103.8M |
| Q1 2025 | -$127.3M |
| Q2 2025 | $113.5M |
| Q3 2025 | $284.7M |
| Q4 2025 | $194.4M |
| Q3 2026 | $271.2M |
Operating cash flow minus capital expenditure, from cash flow statements.
| Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 | Q3 2026 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $593.2Md | $594.2M | $773.7M | $1.2B | $1.1Bd | — | $1.3B | $1.5B |
| Operating income | -$105.2Md | $18.1M | -$16.2M | $368.0M | $131.7Md | — | $231.4M | $345.8M |
| Operating margin | -17.7% | 3.0% | -2.1% | 29.5% | 12.0% | — | 17.9% | 23.7% |
| Net income | -$83.8Md | -$18.3M | -$72.2M | $292.7M | $111.5Md | $206.0M | $164.5M | $2.2B |
| Diluted EPS | — | -$0.14 | -$0.55 | $2.14 | — | — | $1.21 | $15.72 |
| Operating cash flow | -$94.7Md | -$118.3M | $127.8Md | $296.9Md | $217.7Md | — | — | $341.0Md |
| Capital expenditure | $9.1Md | $9.0M | $14.3Md | $12.1Md | $23.3Md | — | — | $69.8Md |
| Free cash flow | -$103.8M | -$127.3M | $113.5M | $284.7M | $194.4M | — | — | $271.2M |
| R&D expense | $300.2Md | $265.1M | $323.6M | $358.8M | $372.2Md | — | $413.1M | $408.5M |
From XBRL data in 10-Q and 10-K filings. d derived: a fourth quarter is the full year minus the first nine months, and cash flows are year-to-date figures differenced.
10-K and 10-Q filings
- 29 Oct 202610-Q for the period ended 30 Sep 2026SEC ↗
- 30 Jul 202610-Q for the period ended 30 Jun 2026SEC ↗
- 30 Apr 202610-Q for the period ended 31 Mar 2026SEC ↗
- 12 Feb 202610-K for the period ended 31 Dec 2025SEC ↗
- 30 Oct 202510-Q for the period ended 30 Sep 2025SEC ↗
- 31 Jul 202510-Q for the period ended 30 Jun 2025SEC ↗
- 1 May 202510-Q for the period ended 31 Mar 2025SEC ↗
- 13 Feb 202510-K for the period ended 31 Dec 2024SEC ↗